Interventions for waterpipe smoking cessation.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
07 06 2023
07 06 2023
Historique:
pmc-release:
07
06
2024
medline:
9
6
2023
pubmed:
8
6
2023
entrez:
7
6
2023
Statut:
epublish
Résumé
While cigarette smoking has declined globally, waterpipe smoking is rising, especially among youth. The impact of this rise is amplified by mounting evidence of its addictive and harmful nature. Waterpipe smoking is influenced by multiple factors, including appealing flavors, marketing, use in social settings, and misperceptions that waterpipe is less harmful or addictive than cigarettes. People who use waterpipes are interested in quitting, but are often unsuccessful at doing so on their own. Therefore, developing and testing waterpipe cessation interventions to help people quit was identified as a priority for global tobacco control efforts. OBJECTIVES: To evaluate the effectiveness of tobacco cessation interventions for people who smoke waterpipes. We searched the Cochrane Tobacco Addiction Review Group Specialized Register from database inception to 29 July 2022, using variant terms and spellings ('waterpipe' or 'narghile' or 'arghile' or 'shisha' or 'goza' or 'narkeela' or 'hookah' or 'hubble bubble'). We searched for trials, published or unpublished, in any language. We sought randomized controlled trials (RCTs), quasi-RCTs, or cluster-RCTs of any smoking cessation interventions for people who use waterpipes, of any age or gender. In order to be included, studies had to measure waterpipe abstinence at a three-month follow-up or longer. We used standard Cochrane methods. Our primary outcome was abstinence from waterpipe use at least three months after baseline. We also collected data on adverse events. Individual study effects and pooled effects were summarized as risk ratios (RR) and 95% confidence intervals (95% CI), using Mantel-Haenszel random-effects models to combine studies, where appropriate. We assessed statistical heterogeneity with the I This review included nine studies, involving 2841 participants. All studies were conducted in adults, and were carried out in Iran, Vietnam, Syria, Lebanon, Egypt, Pakistan, and the USA. Studies were conducted in several settings, including colleges/universities, community healthcare centers, tuberculosis hospitals, and cancer treatment centers, while two studies tested e-health interventions (online web-based educational intervention, text message intervention). Overall, we judged three studies to be at low risk of bias, and six studies at high risk of bias. We pooled data from five studies (1030 participants) that tested intensive face-to-face behavioral interventions compared with brief behavioral intervention (e.g. one behavioral counseling session), usual care (e.g. self-help materials), or no intervention. In our meta-analysis, we included people who used waterpipe exclusively, or with another form of tobacco. Overall, we found low-certainty evidence of a benefit of behavioral support for waterpipe abstinence (RR 3.19 95% CI 2.17 to 4.69; I
Sections du résumé
BACKGROUND
While cigarette smoking has declined globally, waterpipe smoking is rising, especially among youth. The impact of this rise is amplified by mounting evidence of its addictive and harmful nature. Waterpipe smoking is influenced by multiple factors, including appealing flavors, marketing, use in social settings, and misperceptions that waterpipe is less harmful or addictive than cigarettes. People who use waterpipes are interested in quitting, but are often unsuccessful at doing so on their own. Therefore, developing and testing waterpipe cessation interventions to help people quit was identified as a priority for global tobacco control efforts. OBJECTIVES: To evaluate the effectiveness of tobacco cessation interventions for people who smoke waterpipes.
SEARCH METHODS
We searched the Cochrane Tobacco Addiction Review Group Specialized Register from database inception to 29 July 2022, using variant terms and spellings ('waterpipe' or 'narghile' or 'arghile' or 'shisha' or 'goza' or 'narkeela' or 'hookah' or 'hubble bubble'). We searched for trials, published or unpublished, in any language.
SELECTION CRITERIA
We sought randomized controlled trials (RCTs), quasi-RCTs, or cluster-RCTs of any smoking cessation interventions for people who use waterpipes, of any age or gender. In order to be included, studies had to measure waterpipe abstinence at a three-month follow-up or longer.
DATA COLLECTION AND ANALYSIS
We used standard Cochrane methods. Our primary outcome was abstinence from waterpipe use at least three months after baseline. We also collected data on adverse events. Individual study effects and pooled effects were summarized as risk ratios (RR) and 95% confidence intervals (95% CI), using Mantel-Haenszel random-effects models to combine studies, where appropriate. We assessed statistical heterogeneity with the I
MAIN RESULTS
This review included nine studies, involving 2841 participants. All studies were conducted in adults, and were carried out in Iran, Vietnam, Syria, Lebanon, Egypt, Pakistan, and the USA. Studies were conducted in several settings, including colleges/universities, community healthcare centers, tuberculosis hospitals, and cancer treatment centers, while two studies tested e-health interventions (online web-based educational intervention, text message intervention). Overall, we judged three studies to be at low risk of bias, and six studies at high risk of bias. We pooled data from five studies (1030 participants) that tested intensive face-to-face behavioral interventions compared with brief behavioral intervention (e.g. one behavioral counseling session), usual care (e.g. self-help materials), or no intervention. In our meta-analysis, we included people who used waterpipe exclusively, or with another form of tobacco. Overall, we found low-certainty evidence of a benefit of behavioral support for waterpipe abstinence (RR 3.19 95% CI 2.17 to 4.69; I
Identifiants
pubmed: 37286509
doi: 10.1002/14651858.CD005549.pub4
pmc: PMC10245833
doi:
Substances chimiques
Bupropion
01ZG3TPX31
Varenicline
W6HS99O8ZO
Types de publication
Journal Article
Meta-Analysis
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD005549Subventions
Organisme : FIC NIH HHS
ID : R01 TW010654
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
Int J Environ Res Public Health. 2020 Oct 22;17(21):
pubmed: 33105905
Cochrane Database Syst Rev. 2018 May 31;5:CD000146
pubmed: 29852054
Sci Rep. 2016 May 11;6:25872
pubmed: 27167891
Nicotine Tob Res. 2006 Jun;8(3):339-51
pubmed: 16801292
Cochrane Database Syst Rev. 2019 May 02;5:CD002850
pubmed: 31045250
J Environ Sci Health B. 2013;48(12):1097-102
pubmed: 24007487
Am J Public Health. 2016 Oct;106(10):1773-7
pubmed: 27552262
Med Princ Pract. 2008;17(6):435-9
pubmed: 18836270
Inhal Toxicol. 2016 Nov;28(13):629-635
pubmed: 27780378
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005549
pubmed: 17943865
Med Princ Pract. 2012;21(4):340-4
pubmed: 22414554
Addiction. 2013 Nov;108(11):1873-84
pubmed: 23863044
Tob Control. 2020 Mar;29(2):159-167
pubmed: 30696784
BMC Public Health. 2021 Feb 26;21(1):344
pubmed: 33632181
Addiction. 2005 Mar;100(3):299-303
pubmed: 15733243
Nicotine Tob Res. 2011 Jul;13(7):599-610
pubmed: 21471304
Nicotine Tob Res. 2016 May;18(5):585-9
pubmed: 26681774
Cochrane Database Syst Rev. 2013 May 31;(5):CD009329
pubmed: 23728690
MMWR Morb Mortal Wkly Rep. 2015 Apr 17;64(14):381-5
pubmed: 25879896
Am J Ind Med. 2018 Jun;61(6):543-544
pubmed: 29655207
Addiction. 2018 Dec;113(12):2290-2299
pubmed: 30187978
Trials. 2017 Jan 11;18(1):14
pubmed: 28077163
Tob Control. 2015 Mar;24 Suppl 1:i44-i53
pubmed: 25492935
Tob Control. 2020 May;29(Suppl 3):s155-s162
pubmed: 32321849
Int J Environ Res Public Health. 2018 Aug 26;15(9):
pubmed: 30149668
Am J Drug Alcohol Abuse. 2015;41(4):272-80
pubmed: 26057153
Addict Behav. 2017 Nov;74:127-133
pubmed: 28624697
J Med Internet Res. 2017 Jun 07;19(6):e196
pubmed: 28592394
Nicotine Tob Res. 2021 Nov 5;23(12):2056-2064
pubmed: 34125916
Cochrane Database Syst Rev. 2023 May 24;5:CD000031
pubmed: 37230961
Food Chem Toxicol. 2008 Sep;46(9):2991-5
pubmed: 18573302
Health Educ Behav. 2019 Dec;46(2_suppl):97-105
pubmed: 31742460
J Smok Cessat. 2016 Jun;11(2):116-123
pubmed: 27563356
Cochrane Database Syst Rev. 2017 Mar 31;3:CD001007
pubmed: 28361497
Issues Ment Health Nurs. 2018 Aug;39(8):693-699
pubmed: 29847190
BJOG. 2008 Jan;115(1):91-7
pubmed: 18053105
Int J Tuberc Lung Dis. 2015 Apr;19(4):481-7
pubmed: 25860006
Behav Res Methods. 2012 Jun;44(2):490-502
pubmed: 21960061
Contemp Clin Trials. 2005 Apr;26(2):260-7
pubmed: 15837446
Addict Behav. 2018 Mar;78:94-100
pubmed: 29128712
Cochrane Database Syst Rev. 2019 Oct 29;2019(10):
pubmed: 31684699
Tob Control. 2015 Mar;24 Suppl 1:i13-i21
pubmed: 25618895
Addict Behav. 2011 May;36(5):555-9
pubmed: 21316156
Nicotine Tob Res. 2009 Jul;11(7):806-11
pubmed: 19420278
BMC Public Health. 2011 Apr 19;11:244
pubmed: 21504559
Cochrane Database Syst Rev. 2019 Apr 18;4:CD013308
pubmed: 30997928
Cochrane Database Syst Rev. 2017 Dec 15;12:CD001188
pubmed: 29243221
Drug Alcohol Depend. 2020 Dec 1;217:108346
pubmed: 33075692
Nicotine Tob Res. 2016 May;18(5):777-84
pubmed: 26438650
Int J Epidemiol. 2017 Feb 1;46(1):32-43
pubmed: 27075769
Cochrane Database Syst Rev. 2021 Feb 19;2:CD005084
pubmed: 33605440
Tob Control. 2015 Mar;24 Suppl 1:i3-i12
pubmed: 25298368
Cochrane Database Syst Rev. 2019 Jun 05;6:CD009670
pubmed: 31166007
BMJ. 2015 Apr 17;350:h1991
pubmed: 25888390
Prev Med. 2015 Jul;76:20-5
pubmed: 25773472
Ann Intern Med. 2013 May 7;158(9):667-75
pubmed: 23648948
Cochrane Database Syst Rev. 2015 Jul 31;(7):CD005549
pubmed: 26228266
Am J Prev Med. 2009 Dec;37(6):518-23
pubmed: 19944918
Nicotine Tob Res. 2022 Mar 1;24(4):581-589
pubmed: 34751780
S Afr Med J. 2019 May 31;109(6):392-406
pubmed: 31266557
Addict Behav. 2017 Jan;64:49-53
pubmed: 27543834
Cochrane Database Syst Rev. 2019 Oct 31;2019(10):
pubmed: 31684695
Nicotine Tob Res. 2013 Jan;15(1):231-7
pubmed: 22573726
Cochrane Database Syst Rev. 2019 Jan 09;1:CD001118
pubmed: 30623970
Drug Alcohol Depend. 2015 Aug 1;153:14-21
pubmed: 26054945
Tob Control. 2015 Mar;24 Suppl 1:i31-i43
pubmed: 25661414
Expert Rev Respir Med. 2019 Nov;13(11):1109-1119
pubmed: 31519113
Drug Alcohol Depend. 2020 Oct 1;215:108192
pubmed: 32738447
Cochrane Database Syst Rev. 2021 Jan 4;1:CD013229
pubmed: 33411338
Tob Control. 2018 May;27(3):347-351
pubmed: 28667092
Epidemiol Health. 2018 Mar 13;40:e2018008
pubmed: 29529859
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
J Clin Epidemiol. 2022 Dec;152:285-287
pubmed: 36223813
J Environ Public Health. 2020 Nov 6;2020:2364571
pubmed: 33204280
Addict Behav. 2014 Jun;39(6):1066-74
pubmed: 24629480
Am J Addict. 2018 Apr;27(3):202-209
pubmed: 29569328
PLoS One. 2018 Feb 9;13(2):e0192191
pubmed: 29425207
Cochrane Database Syst Rev. 2017 Sep 04;9:CD007078
pubmed: 28869775
Addiction. 2022 Jun;117(6):1573-1588
pubmed: 34859525
Addict Sci Clin Pract. 2022 Mar 14;17(1):18
pubmed: 35287728
Nicotine Tob Res. 2019 Oct 26;21(11):1524-1530
pubmed: 30335180
JAMA Pediatr. 2015 Feb;169(2):129-36
pubmed: 25485959
Nicotine Tob Res. 2013 Aug;15(8):1372-81
pubmed: 23328881
Circulation. 2019 May 7;139(19):e917-e936
pubmed: 30845826
Cochrane Database Syst Rev. 2023 May 5;5:CD006103
pubmed: 37142273
Cochrane Database Syst Rev. 2016 Mar 24;3:CD008286
pubmed: 27009521
Am J Public Health. 2021 Sep;111(9):1686-1695
pubmed: 34436927
Nicotine Tob Res. 2014 Jun;16(6):682-8
pubmed: 24376277
Cochrane Database Syst Rev. 2013 May 31;(5):CD000165
pubmed: 23728631
Cochrane Database Syst Rev. 2019 Jul 17;7:CD004307
pubmed: 31313293
Int J Prev Med. 2019 Jun 12;10:111
pubmed: 31360358
Nicotine Tob Res. 2023 Jan 1;25(1):111-119
pubmed: 35789389
Drug Alcohol Depend. 2015 Oct 1;155:128-33
pubmed: 26297296
Cochrane Database Syst Rev. 2002;(3):CD001292
pubmed: 12137623
JAMA. 2022 Feb 08;327(6):566-577
pubmed: 35133411
Cochrane Database Syst Rev. 2019 Oct 22;10:CD006611
pubmed: 31638271